Selecta Biosciences (NASDAQ:SELB) has announced an agreement to transition the manufacturing and development rights and remaining clinical operations of ImmTOR for SEL-212 to its partner, Swedish Orphan Biovitrum AB (Sobi). As of November 6, 2023, Sobi will assume responsibility for the manufacturing and commercial supply of ImmTOR for SEL-212. Selecta believes this transition will streamline its organization and optimize the value of its SEL-212 royalty stream for stockholders. Selecta is eligible to receive up to $615.0 million in remaining regulatory and commercial milestone payments and tiered double-digit royalties on net sales of SEL-212.